Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (91-100 of 288) with videos related to

Pageof 29
Sort By:
Journal of the National Cancer Institute|September 26, 2014
Impact of prior cancer on eligibility for lung cancer clinical trialsDavid E Gerber, Andrew L Laccetti, Lei Xuan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysisAndrew L Laccetti, Sandi L Pruitt, Lei Xuan, et al.
Journal of the National Cancer Institute|February 11, 2015
Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrualAndrew L Laccetti, Sandi L Pruitt, Lei Xuan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancerKristin N Arreola, James Ying, Randall Hughes, et al.
The Oncologist|May 29, 2015
Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved PopulationsDavid E Gerber, Ashley M Lakoduk, Laurin L Priddy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2017
Therapeutic Targeting of Nuclear Export Inhibition in Lung CancerArjun Gupta, Jessica M Saltarski, Michael A White, et al.
British Journal of Cancer|February 15, 2017
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancerSandi L Pruitt, Andrew L Laccetti, Lei Xuan, et al.
Cancer|July 6, 2018
Statistical justification of expansion cohorts in phase 1 cancer trialsAli A Mokdad, Xian-Jin Xie, Hong Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibitionTri Le, Joseph Sailors, Dwight H Oliver, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Targeted therapies for lung cancer: clinical experience and novel agentsJill E Larsen, Tina Cascone, David E Gerber, et al.
Pageof 29

Showing results (91-100 of 288) with videos related to

Sort By:
Pageof 29
Journal of the National Cancer Institute|September 26, 2014
Impact of prior cancer on eligibility for lung cancer clinical trialsDavid E Gerber, Andrew L Laccetti, Lei Xuan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysisAndrew L Laccetti, Sandi L Pruitt, Lei Xuan, et al.
Journal of the National Cancer Institute|February 11, 2015
Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrualAndrew L Laccetti, Sandi L Pruitt, Lei Xuan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancerKristin N Arreola, James Ying, Randall Hughes, et al.
The Oncologist|May 29, 2015
Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved PopulationsDavid E Gerber, Ashley M Lakoduk, Laurin L Priddy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2017
Therapeutic Targeting of Nuclear Export Inhibition in Lung CancerArjun Gupta, Jessica M Saltarski, Michael A White, et al.
British Journal of Cancer|February 15, 2017
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancerSandi L Pruitt, Andrew L Laccetti, Lei Xuan, et al.
Cancer|July 6, 2018
Statistical justification of expansion cohorts in phase 1 cancer trialsAli A Mokdad, Xian-Jin Xie, Hong Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibitionTri Le, Joseph Sailors, Dwight H Oliver, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Targeted therapies for lung cancer: clinical experience and novel agentsJill E Larsen, Tina Cascone, David E Gerber, et al.
Pageof 29